Emily Brown on Muck Rack

Emily Brown

As seen in: Color Research & Application, Wiley Online Library, Memory Studies, BMJ Open, BMJ Open Diabetes Research & Care, Chicago Tribune, The BMJ, JAMA Network, Phys.org, HuffPost UK and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Emily

Contact Emily, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Rapid Respiratory Microbiological Point-of-Care Testing and Antibiotic Use in Primary Care : A Randomized Clinical Trial

|
By Alastair D Hay, Samantha Elizabeth Abbs, Matthew J Ridd, Stephen Granier, J. Athene Lane, Peter Muir, Jodi Taylor, Grace Young, Kathy Eastwood, Lynne Bradshaw, Rebecca Clarke, Emma Bridgeman, Emily Brown, Hannah V Thornton, Paul Mitchell, Liang Zhu, Lucy Yardley, Chris Metcalfe, Hayley Dash, Mandy Lui, Rachel C. M. Brierley
| JAMA Network Verified
Rapid Respiratory Microbiological Point-of-Care Testing and Antibiotic Use in Primary Care: A Randomized Clinical Trial Supplement 1. Trial Protocol and Statistical Analysis Plan Supplement 2. eFigure 1. Study procedures eAppendix 1. Trial diary (adult) eAppendix 2. Trial diary (child) eAppendix 3. Interpreting BioFire results: information for clinicians eFigure 2. Kaplan-Meier curve of moderately bad, or worse symptom duration by group eFigure 4.
Open in Who Shared Issue with article?

Top FDA Gene and Cell Therapy News: 2025 Year-End Recap

|
By Steven W Pipe, Noah Stansfield, Emily Brown, Isabella Ciccone
| CGTLive
As 2025 comes to a close, CGTLive has looked back on some of the most-read and most impactful FDA regulatory decisions and news in the cell and gene therapy space. These approvals and regulatory actions marked major progress for patients with previously limited or no treatment options, and also reflected increasing FDA flexibility in areas of rare disease, novel delivery mechanisms, and advanced biologics manufacturing.
Open in Who Shared Issue with article?

Rutgers and Iovance Assess E7 TCR T-Cell Therapy in Phase 1/2 Trial for HPV-Associated Tumors

|
By Steven W Pipe, Noah Stansfield, Emily Brown, Isabella Ciccone
| CGTLive
Rutgers and collaborator Iovance Therapeutics are currently evaluating an E7 T-cell receptor (TCR)-T cell therapy (referred to as “E7 TCR-T cells”) for the treatment of various locoregionally advanced HPV-associated tumors in a phase 1/2 clinical trial (NCT05639972).1 For this installment of Clinical Trials in Progress, CGTLive® is taking a closer look at this ongoing study. The trial, which was launched on August 11, 2025, has an estimated completion date of October 1, 2026.
Open in Who Shared Issue with article?
See all 205 licensed articles (211 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified